CircPTK2 (hsa_circ_0005273) as a novel therapeutic target for metastatic colorectal cancer

Hongbao Yang¹, Xiaobo Li², Qingtao Meng², Hao Sun², Shenshen Wu³,⁴, Weizi Hu¹, Guilai Liu¹, Xianjing Li¹, Yong Yang¹,⁵* and Rui Chen²,³,⁴*

Abstract

Background: As a novel class of noncoding RNAs, circRNAs have been recently identified to regulate tumorigenesis and aggressiveness. However, the function of circRNAs in colorectal cancer (CRC) metastasis remains unclear. We aimed to identify circRNAs that are upregulated in CRC tissues from patients and study their function in CRC metastasis.

Methods: We compared six pairs of CRC tissues and their matched adjacent non-tumor tissues by using circRNA microarray. We first evaluated the expression of circPTK2 (hsa_circ_0005273) in fresh tissues from CRC tumors and corresponding adjacent tissues by qPCR analysis. CircPTK2 expression levels in the tissue microarray with 5 years of survival information were determined by RNA-ISH analysis. Meanwhile, the expression levels of circulating circPTK2 were further analyzed according to the patients’ clinical features. We analyzed cell apoptosis, colony formation, migration, and invasion in CRC cells. To further elucidate the effect of circPTK2 in CRC metastasis, we also conducted a colon cancer hepatic and pulmonary metastasis experiment. We used RNA biotin-labeled pull down and mass spectrometry to identify the target of circPTK2. We established a PDTX model to evaluate the effect of shRNA specifically targeting circPTK2 on tumor metastasis.

Results: We identified a novel circRNA, circPTK2, which is back-spliced of three exons (exons 27, 28 and 29) of PTK2 by using circRNA microarray, bioinformatics and functional studies. CircPTK2 was elevated in CRC tissues and positively associated with tumor growth and metastasis. CRC patients with increased circPTK2 expression were positively correlated with poorer survival rates. Furthermore, our studies showed that circPTK2 could promote EMT of CRC cells in vitro and in vivo by binding to vimentin protein on sites Ser38, Ser55 and Ser82. We further demonstrated the interaction of circPTK2 and vimentin mediated the regulation of CRC by knockdown or overexpression of vimentin. In addition, we revealed that tail vein injection of shRNA specifically targeting circPTK2 blunt tumor metastasis in a patient-derived CRC xenograft model.

Conclusions: Collectively, these results demonstrate that circPTK2 exerts critical roles in CRC growth and metastasis and may serve as a potential therapeutic target for CRC metastasis, and also a promising biomarker for early diagnosis of metastasis.

Keywords: CRC, circRNA, circPTK2, EMT, Vimentin
Background

Colorectal cancer (CRC) is the third most common and second leading cause of cancer death in the world [1]. Although significant progress has been made in the treatment of CRC in recent decades, the prognosis is still poor, especially in the distant metastasis of advanced-stage tumors [2, 3]. Therefore, finding novel potential biomarkers for early diagnosis and prediction of CRC metastasis and further elucidating the precise molecular mechanisms can provide improved treatment for CRC patients.

Circular RNAs (circRNAs), a class of non-coding RNAs, are characterized by a covalent bond linking the 3’and 5’ ends generated by backsplicing [4]. Most circRNAs result from a non-canonical form of alternative splicing, a process mediated by spliceosomes or by group I and group II ribozymes [5]. Genome-wide analyses of RNA sequencing data have shown evolutionary conservation and abundance of circular RNAs [6, 7]. CircRNAs can be generated from exons, called exonic circular RNAs [6, 8], or from introns, called intronic circular RNAs, or a mix of both called circRNAs [9, 10]. CircRNAs have been found to function as endogenous miRNA sponges since some circRNAs possess miRNA binding sites, allowing them to arrest miRNA activity [11]. Besides, circRNAs also function as RNA-binding protein (RBP) sequestering agents as well as transcription regulators to modulate gene expressions [12–14]. Emerging evidences suggest that circRNAs are closely related to human diseases, especially cancers, and can serve as better biomarkers because of their abundance and stability. Recently, several circRNAs have been found to be associated with CRC tumorigenesis or metastasis, such as circCCDC66, hsa_circ_001569, ciRS-7-A, and circHIPK3 [15–19]. These studies demonstrate that the regulation of circRNA expression is tightly controlled under distinct circumstances, and that the investigations into circRNA are still in their infancy. The functions and underlying mechanisms of circRNAs in the epithelial–mesenchymal transition (EMT) process of human cancers, such as CRC, remain unclear. EMT is the key to tumor metastasis [20, 21]. EMT converts epithelial cells to a mesenchymal-like phenotype and is associated with the loss of cell contacts, production of the type-III intermediate filament protein vimentin, and increases in cell migration and invasion [22].

In this study, we identified a molecular effector mechanism of circPTK2 (hsa_circ_0005273 in circBase: http://www.circbase.org) in CRC using circRNA microarray, bioinformatics, and functional studies. We found that circPTK2 was elevated in CRC tissues and positively associated with tumor growth and metastasis. CRC patients with increased circPTK2 expression were positively correlated with poorer survival rates. Further mechanism studies showed that circPTK2 could promote EMT of CRC cells in vitro and in vivo by targeting vimentin protein on sites Ser38, Ser55 and Ser82. We further demonstrated that the interaction of circPTK2 and vimentin mediated the regulation of CRC by knockdown or overexpression of vimentin. In addition, we showed that tail vein injection of shRNA specifically targets circPTK2 blunt tumor metastasis in a patient-derived CRC xenograft model. In concert, we identified that circPTK2 is a promising biomarker for early diagnosis of CRC metastasis and provides a potential therapeutic target for CRC.

Methods

Patients and specimens

All samples used in this study were in compliance with the informed consent and agreement of patients as well as the ethical regulations (No. 2017ZDKYSB165) of Southeast University, China.

Fresh tumor tissue and corresponding adjacent non-cancerous tissues were collected from CRC patients, which included a test set (consisting of 61 CRC cases enrolled from the Jiangsu Tumor Hospital) and a validation set (consisting of 131 CRC cases enrolled from the Affiliated Hospital of the Xuzhou Medical College), between 2014 and 2016. Tumor stage was defined according to the criteria of the sixth edition of TNM classification of the International Union Against Cancer (UICC, 2009). Detailed information of CRC patients is presented in Additional file 7: Table S1.

To determine whether circRNA serves as a blood-based early biomarker for CRC detection, peripheral blood samples were collected simultaneously with the tumor tissues mentioned above. Meanwhile, peripheral blood samples were also collected from sex- and age-matched healthy donors enrolled from the Nanjing Hospital of Chinese Medicine from 2014 to 2016. Criteria for healthy control exclusion included those with a history of diabetes, obesity (BMI over 30), hypertension (systolic blood pressure over 120 mm of mercury (mm Hg) and/or diastolic blood pressure over 80 mmHg), clinically diagnosed chronic cardiovascular diseases, chronic kidney diseases, chronic gastrointestinal diseases, and respiratory diseases. Detailed information of healthy control is presented in Additional file 7: Table S1. Because the total RNA extracted from six samples was unqualified, and six blood samples were not collected, these samples were not counted in. Therefore, the sample size finally included in the statistics is 186.

For the construction of tissue microarray (TMA), the CRC and adjacent non-tumor tissues (5 cm from the tumor margins) were collected from two independent cohorts as previously reported [23]. The test cohort (376 patients) was recruited from the Affiliated Hospital of
Xuzhou Medical College between 2007 and 2011. A validation cohort consisting of 702 patients was recruited from the Jiangsu Tumor Hospital between 2007 and 2011. All of the patients were followed-up by a trained clinical specialist through in-person or family contact from the time of diagnosis to death, or last follow-up (the last follow-up was in June 2016). The maximum follow-up time was 112.7 months and the median survival time (MST) was 75.0 months. Detailed information on these patients is listed in Additional file 8: Table S2 [23]. Because 105 samples were lost during antigen retrieval or without relevant cells present in the core, the number of sample size finally included in the statistics is 973.

Cell culture and in vitro experiments
Human CRC cell lines (HCT15, SW620, SW480 and LOVO) and 293 T were purchased from American Type Culture Collection (ATCC) (Manassas, VA).

Details are provided in Additional file 10.

CircRNA microarray
Six pairs of CRC tissues (3 colon and 3 rectal carcinomas) and the corresponding adjacent noncancerous tissues, as well as six adenomas (all tubulovillous adenomas) were utilized for circRNA microarrays. The specimens were obtained from patients undergoing surgery in the Jiangsu Tumor Hospital in 2015; detailed information is shown in Additional file 9: Table S3.

Details are provided in Additional file 10.

Tissue/serum preparation and RNA isolation
Details are provided in Additional file 10.

RNAscope
circPTK2 expression levels in CRC cells, fresh paraffin-embedded tissues, and TMA were assayed with the BaseScopeTM Reagent Kit v2-RED (Advanced Cell Diagnostics, Newark, CA) according to the manufacturer’s instructions. Briefly, samples were incubated with circPTK2 probes (NM_153831.3, nt2804–2485) at 40 °C for 2 h. For the fresh paraffin-embedded tissues, the samples were rehydrated for 15 min and digested with protease for 30 min before incubation with the probe. After hybridization, a series of single amplification procedures were performed. circPTK2 expression levels were ultimately visualized with Fast Red.

CircRNA in situ hybridization (RNA-ISH)
Tissue microarray (TMA) slides were de-paraffinized using xylene for three 5-min washes; rehydrated with an ethanol gradient via 5-min washes in 100, 95, and 80% ethanol; and then treated with 20 μg/mL Proteinase K (Roche Diagnostics, Indianapolis, IN) for 10 min at 37 °C. After that, the slides were fixed in 4% formaldehyde (Thermo Scientific, Rockford, IL) for 10 min, rinsed twice using 0.13 M 1-methylimidazole, and re-fixed with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC, Thermo Scientific) for 1 h. The 1% H2O2 was used to block endogenous peroxidases, and the slides were prehybridized at 50°C for 30 min in the hybridization buffer [50% formamide (American Bioanalytical), 5 × SSC (American Bioanalytical, Natick, MA), 50 μg/mL heparin (Sigma-Aldrich, St. Louis, MO), 0.1% Tween 20 (Sigma-Aldrich, St. Louis, MO), and 500 μg/mL yeast tRNA (Invitrogen, Carlsbad, CA), with a pH = 6. Next, the slides were hybridized with 200 nM double digoxigenin (DIG) LNA modified.

The staining of circPTK2 in the TMA was scored independently by two pathologists blinded to the clinical data using the following criterion: Category A: the intensity of immunostaining was scored from 0 to 3 (0, negative; 1, weak; 2, moderate; and 3, strong); Category B: the percentage of immunoreactive circPTK2 was deemed as 1 (0–25%), 2 (26–50%), 3 (51–75%), and 4 (76–100%). The circPTK2 score was calculated by multiplying Category A and Category B.

In vivo experiments
All animal experiments were conducted with the approval of the Center for New Drug Evaluation and Research, China Pharmaceutical University (Nanjing, China) in a 12-h light and 12-h dark turnover environment, and in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The animals were housed in standard pathogen-free (SPF) conditions at 24 °C ± 2 °C, with 40 to 70% relative humidity. Water and a basal diet were given ad libitum. The nude mice were purchased from the Model Animal Research Center of Nanjing University (China). Of note, 5 × 10⁶ cells less than 15 passage after the initial drug selection were implanted in the flank site of 6-week-old female nude mice (n = 3/group). Fourteen days later, images were taken by an in vivo imaging system (IVIS) Spectrum (PerkinElmer, USA). The tumor, liver, and lung tissues were harvested, and the biochemical luciferase activities in the homogenate of tissues were determined by a luminometer (Sirius, Berthold Detection Systems, Germany).

Quantitative real-time PCR analysis
For mature circRNA expression analysis, 1 μg of total RNA was converted to cDNA using a One Step PrimeScript® circRNA cDNA Synthesis Kit (Takara, Shiga, Japan). After reverse transcription, quantitative real-time PCR analysis was performed using the SYBR Premix Ex Taq kit (Takara, Shiga, Japan) along with the specific circRNA LNA™ PCR primer sets designed by Exiqon.
cell extracts from CRC cells at room temperature (RT) for slides were analyzed with a light microscope. action and counterstained with hematoxylin. Finally, the diaminobenzidine (DAB) substrate kit for peroxidase reaction. Staining was performed using 3, 3-

For western blotting assays, proteins isolated from tissues were incubated with primary antibody detecting vimentin and E-cadherin (1:1000 dilution; cell signaling), and β-actin (1:1000 dilution; cell signaling) was used as a control.

siRNA, shRNA, and plasmid construction and cell transfection
siRNAs targeting circPTK2 and vimentin were designed and synthesized by Ribobio (Guangzhou, China).

Immunohistochemistry (IHC) staining
Tissues were fixed with 4% paraformaldehyde, dehydrated, embedded in paraffin and sectioned at 4 μm. Sections were deparaffinized, rehydrated and incubated with 3% H₂O₂. After antigen repair and being blocked, the slides were incubated with rabbit monoclonal antibody against vimentin (1:100) (Cell Signaling Technology, USA) at 4 °C overnight. Subsequently, the slides were incubated with secondary antibody at room temperature for 30 min and then incubated with streptavidin peroxidase complex. Staining was performed using 3, 3-diaminobenzidine (DAB) substrate kit for peroxidase reaction and counterstained with hematoxylin. Finally, the slides were analyzed with a light microscope.

Biotin-labeled RNA pull-down and mass spectrometry analysis
Biotin-labeled RNA for liner sequence of circPTK2 was generated by in vitro transcription reaction with the Biotin RNA Labeling Mix (Roche, Mannheim, Germany) and T7 RNA polymerase (Roche, Mannheim, Germany), and then treated with RNase-free DNase I (Takara, Japan). After incubation with guide oligonucleotide targeting circular junction, the linear probe was then circularized using T4 RNA ligase I, treated with RNase R. After purified with RNeasy Mini Kit (Qiagen, Inc., Valencia, CA, USA), the biotin-labeled RNA probe (3 μg) was then incubated with cell extracts from CRC cells at room temperature (RT) for 2 h, and treated with 35 μl of Streptavidin C1 magnetic beads (Invitrogen) for 1 h. after washed, the retrieved protein was detected by western blot or mass spectrometry analysis (CapitalBio Technology, Beijing, China).

Patient-derived tumor xenograft (PDTX) models
Briefly, fresh human CRC tissues were washed twice with cold PBS containing penicillin (500 U/mL) and streptomycin (500 μg/mL), and transplanted subcutaneously into the right flanks of NCG mice. When the tumor volume reached 250 mm³ (V = 0.5 × length × width²), xenografts were resected and passaged into additional NCG mice. Successfully xenografted CRC tumor models were passaged and banked after three passages in vivo. For isolation of the PDTX tumor cells, xenografts were disaggregated mechanically, and washed twice using PBS with penicillin (500 U/mL), streptomycin (500 μg/mL), gentamicin (100 mg/L), and amphotericin B (2.5 mg/L). Next, the tumor mass was digested in culture medium containing type II/IV collagenase (1 mg/mL) and DNase (1 mg/mL) at 37 °C for 1 h with gentle shaking. After filtration through a 80 μm filter (BD Biosciences, San Jose, CA), the cell suspension was centrifuged at 300 g for 5 min at 4 °C. The pellets were resuspended using Dulbecco’s Modified Eagle Medium (DMEM) and seeded in 6-well plates for further experimentation. Subsequently, mice bearing lower circPTK2-expressing xenografts were injected with control and circPTK2-overexpressing lentivirus by tail vein, whereas mice bearing higher circPTK2-expressing xenografts were injected with control and circPTK2 shRNA lentivirus by tail vein. Twenty-one days later, mice were killed and liver sections were subjected to H&E staining and autofluorescence assay.

Analysis of cell colony formation, invasion, migration ability, and apoptosis
Details are provided in Additional file 10.

Statistical analysis
Data are shown as mean ± standard error of the mean (SE). The 2−ΔΔCt method was used to analyze the results of real-time PCR in all of the experiments. Differences in the circRNA levels of the tissues were analyzed using the Wilcoxon rank-sum test. The receiver operating characteristic (ROC) curves plotted by R package’s “pROC” were applied to estimate the diagnostic value of CIRC on CRC detection [Robin X, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12, 77 (2011)]. The time-dependent ROC curve analysis was used to calculate the best cutoff value of circRNA. The different values of the follow-up time were evaluated through the performances of different scores by plotting (t, AUC[T]).
The probability of difference in overall survival (OS) was ascertained by Kaplan-Meier curves, and the significance was detected by a log-rank test. Univariate or multivariate Cox regression analysis was applied to estimate the crude hazard ratios (HRs), adjusted HRs, and corresponding 95% confidence intervals (CIs). Statistical analysis was performed using SAS software 9.4, GraphPad Prism, and significance was set at $P < 0.05$.

**Results**

**Expression profiles of circRNAs in CRC**

To characterize circRNA expression profiles in CRC tissues, we compared six pairs of CRC tissues and their matched adjacent non-tumor tissues by using circRNA microarray. As a result, 30 circRNAs ($P < 0.05$ and fold change $> 2.0$) and their host gene mRNAs ($P < 0.05$ and fold change $> 1.5$) were upregulated between the CRC tumor tissues and paired adjacent normal tissues. The top 30 upregulated circRNAs were shown by hierarchical clustering (Fig. 1a).

In this study, circPTK2 (chr8:141710989-141716304) was estimated as the seventh highly upregulated circRNA in CRC, with a more than six-fold change from microarray analysis. By browsing the human reference genome (GRCh37/hg19), we identified that circPTK2 is back-spliced of three exons (exons 27, 28, and 29) of PTK2 (Fig. 1b). The human gene PTK2, encoding FAK, is localized at chromosome 8q24.3, a region characterized by frequent aberrations in human cancers. Focal adhesion kinase (FAK) is a multifunctional regulator of cell signal transduction in the tumor microenvironment. FAK promotes cell migration, survival, and proliferation through kinase-dependent and -independent mechanisms in various tumors. Elevated levels of FAK are related to the progression of multiple malignant tumors, and its role in regulating cell proliferation, migration, and apoptosis has been extensively studied [24–27].

We detected the localization of circPTK2 in cells or tissues. Using RNAscope ISH, we found that circPTK2 existed in both cytoplasm and nucleus (Fig. 1c and e). Hypoxia is one of the most common stressors encountered within the tumor microenvironment. Here, we used hypoxia to mimic the tumor microenvironment and detected the expression or location alteration under the hypoxic condition. We found that the expression of circPTK2 significantly accumulated after hypoxic induction, whereas the location was not changed, whether in high-level circPTK2 cells (SW620 or LOVO cells) or low-level circPTK2 cells (SW480 or HCT15 cells) (Fig. 1c, d, e, and f). Interestingly, results from tissues showed that circPTK2 existed only in tumor tissues, not in normal tissues (Fig. 1g).

CircPTK2 is elevated in both CRC tissues and serum and associated with tumor metastasis

To determine whether circPTK2 participates in CRC, we first evaluated the expression of circPTK2 in fresh tissues from CRC tumors (CRC) and corresponding adjacent tissues. qPCR analysis showed that the abundance of circPTK2 in CRC tissues was markedly elevated compared to adjacent tissue in the testing, validation, and combination sets (Fig. 2a). Moreover, dramatically higher tumoral circPTK2 levels were found in patients with lymph node or distal metastases (Fig. 2b). No significant difference in circPTK2 levels was detected in patients with primary tumors (Fig. 2b). Furthermore, circPTK2 expression levels in the TMA with 5 years of survival information (containing 1078 pairs of CRC tissues and matched adjacent noncancerous tissues) were determined by RNA-ISH analysis. As shown in Fig. 2c and d, circPTK2 levels were significantly overexpressed in CRC tissues compared with adjacent non-tumor tissues. In addition, higher tumoral circPTK2 levels correlated with shorter OS time (Fig. 2e).

Meanwhile, the levels of serumal circPTK2 expression were further analyzed according to the patients’ clinical features. Consistent with the results in tissues, the abundance of circPTK2 in CRC serum was markedly elevated compared to the serum from healthy controls (NOR) in the testing, validation, and combination sets (Additional file 1: Figure S1A). In addition, patients with node or distal metastases exhibited the elevated abundance of circPTK2 in serum (Additional file 1: Figure S1B). Furthermore, ROC analysis showed that circPTK2 is indicative of CRC in patients with node or distal metastases (Additional file 1: Figure S1C). Taken together, our results indicate that tumoral circPTK2 is associated with poor clinical features, including metastasis, in CRC patients.

CircPTK2 promoted aggressive phenotypes of CRC cells in vitro

To investigate the roles of circPTK2 in malignant phenotypes, we analyzed cell apoptosis, colony formation, migration, and invasion in CRC cells. Firstly, we detected the expression levels of circPTK2 in CRC cell lines with different metastatic potential. Enhanced signals were found in SW620 cells (with high metastatic potential) than in SW480 cells (derived from the primary lesion). circPTK2 knockdown significantly decreased the apoptosis in SW620 cells (Fig. 3a, b), but not in SW480 cells (Additional file 2: Figure S2A, B). On the contrary, circPTK2 overexpression increased the apoptosis in SW480 cells (Fig. 3c, d), but not in SW620 cells (Additional file 2: Figure S2C, D). Moreover, colony formation, migration, and invasion assays showed that circPTK2 knockdown significantly inhibited the proliferative, migrant, and invasive capacity of SW620 and
LOVO cells (Fig. 3e, f, i, j and Additional file 2: Figure S2E, F, I, J). These results were confirmed by circPTK2 overexpression in SW480 and HCT15 cells (low-level circPTK2) (Fig. 3g, h, k, l, and Additional file 2: Figure S2G, H, K, L).

**CircPTK2 promoted tumor growth and metastasis in vivo**

To evaluate the functional role of circPTK2 in CRC, a luciferase-expressing SW620 colon tumor cell line, was used to generate tumors orthotopically in female nude mice. Ex vivo imaging of organs showed a significant decrease in tumor cell burden in the primary location, liver, and lung associated with circPTK2 knockdown (Fig. 4a, b). These data were confirmed by grafting mice with luciferase-expressing LOVO cell line (Additional file 3: Figure S3A, B). To further elucidate the effect of circPTK2 in CRC metastasis, we also conducted a colon cancer hepatic and pulmonary metastasis experiment. Results showed that circPTK2 knockdown significantly blunted the spontaneous hepatic metastasis following intrasplenic injection or lung metastasis following tail vein injection of SW620, respectively (Fig. 4c, d). Together, these data suggested that circPTK2 knockdown inhibited the capacity of tumorigenesis and metastasis. Finally, overexpression assay showed that artificial
accumulation of circPTK2 enhanced the capacity of tumor growth and metastasis in vivo (Fig. 4e, f, g, h, and Additional file 3: Figure S3C, D).

CircPTK2 targeted vimentin protein to regulate the growth and metastasis of CRC

To investigate the mechanism by which circPTK2 regulates the tumorigenesis, growth, and metastasis of CRC, we used RNA biotin-labeled pulldown and mass spectrometry to identify the target of circPTK2. Fortunately, we found vimentin protein significantly bound with circPTK2 (Fig. 5b, c and Additional file 4: Figure S4). The expression level of circPTK2 is significantly correlated with vimentin (Fig. 5a). Dual RNAscope and IHC assay confirmed the co-localization of circPTK2 and vimentin in CRC tissues (Fig. 5e). In addition, western blotting results showed that circPTK2 overexpression markedly promoted vimentin, MMP2/9 and CXCR4 expression in SW480 and HCT15 cells, and significantly decreased the E-cadherin expression (Fig. 5d and Additional file 6: Figure S6). Furthermore, we confirmed the target sites for circPTK2 on vimentin by RNA pulldown and western blotting with antibodies against vimentin (phosphor Ser38, Ser55, Ser72, Ser82), we found circPTK2 bound to vimentin on sites Ser38, Ser55 and Ser82, rather than Ser72 (Fig. 5f).

To determine whether the binding of circPTK2 and vimentin protein functionally mediated the regulation of
CRC growth and metastasis, we first stably overexpressed the circPTK2 in SW480 and HCT15 cells (low-level circPTK2), sequentially followed by knocking down vimentin expression with siRNA. Results showed that vimentin knockdown markedly blocked the effect of circPTK2 expression in colony formation and tumor cell burden (Fig. 5g, h, and Additional file 5: Figure S5A, B). Similar results were acquired in SW620 and LOVO cells (high-level circPTK2) that vimentin overexpression significantly increased colony formation and tumor cell burden, which downregulated by the knockdown of circPTK2 (Fig. 5i, j, and Additional file 5: Figure S5C, D).

Fig. 3 CircPTK2 promoted aggressive phenotypes of CRC cells in vitro. Cells were transfected with circPTK2 siRNA or circPTK2- overexpressing plasmid for 48 h. Then cells were harvested for annexin-V and PI staining. Cell apoptosis was detected with flow cytometry analysis. The cells were stained by crystal violet to evaluate cell proliferation, migration, and invasion capability. a, b The effect of circPTK2 knockdown on SW620 apoptosis. c, d The effect of circPTK2 overexpression on SW480 apoptosis. e-h Representative images and quantification results of the colony formation of cells. i-l Representative images and quantification results of the migration and invasion of cells. The data are the mean ± SEM. *P< 0.05, **P<0.01, ***P<0.001. P values were calculated by one-way ANOVA.
Fig. 4  CircPTK2 promoted tumor growth and metastasis in a xenograft mouse model. SW620 or SW480 cells stably expressing luciferase were transfected with the indicated siRNAs or the indicated overexpressing-plasmid. After 72 h, cells were injected into the tail veins of nude mice (n = 6). a Representative bioluminescence images of mice bearing SW620 cells were obtained. b Luciferase activity of tumor, liver and lung was quantified in mice bearing SW620 cells. c SW620 cells, transfected with the indicated siRNAs, were injected to spleen of mice. After 21 and 42 days, livers were obtained. Representative images of liver and its HE staining were shown. d SW620 cells were injected into the tail veins of nude mice. After 7 and 14 days, lungs were obtained. Representative images of lung and its HE staining are shown. e Representative bioluminescence images of mice bearing SW480 cells were obtained. f Luciferase activity of tumor, liver and lung was quantified in mice bearing SW480 cells. g SW480 cells, transfected with the indicated overexpressing-plasmid, were injected to spleen of mice. After 21 and 42 days, livers were obtained. Representative images of liver and its HE staining are shown. h SW480 cells were injected into the tail veins of nude mice. After 7 and 14 days, lungs were obtained. Representative images of lung and its HE staining are shown. The data are the mean ± SEM. *P<0.05, **P<0.01, ***P<0.001. P values were calculated by one-way ANOVA.
shRNA specifically targeting circPTK2 significantly inhibited tumor metastasis in a patient-derived tumor xenograft (PDTX) model of CRC

We established a PDTX model using primary tumor cells isolated from 24 CRC patients (Fig. 6a). Firstly, we confirmed that the expression levels of circPTK2 were equal between the original donor patients and isolated cells from the PDTX (Fig. 6b). Based on the screening, we chose six highest and six lowest circPTK2-expressing tumor tissue for the further functional assays (Fig. 6c), and we detected the expression level of vimentin in three highest and three lowest circPTK2-expressing tumor tissues by IHC. Results showed that the expression of vimentin significantly increased in high-level circPTK2 tumor tissue and obviously decreased in low-level circPTK2 tumor tissue (Fig. 6d). Subsequently, mice bearing lower circPTK2-expressing xenografts were injected with control and circPTK2-overexpressing lentivirus by tail vein, whereas mice bearing higher circPTK2-
Fig. 6 (See legend on next page.)
expressing xenografts were injected with control shRNA and circPTK2 shRNA lentivirus by tail vein. Results showed that the migration and invasion was decreased by circPTK2 knockdown, whereas they were increased by circPTK2 overexpression (Fig. 6e and f). Similar results were obtained in liver metastasis following intrasplenic injection of tumor cells isolated from the PDTX model, in parallel with results from injection of cell line (Fig. 6g and h).

Discussion
In this study, we found circPTK2, a circRNA derived from PTK2 gene with unknown molecular functions, was elevated and associated with poor prognosis. In vitro and in vivo studies showed that circPTK2 possesses oncogenic capability according to promoting cell proliferation, migration, and metastasis. To the best of our knowledge, this is the first report that exhaustively investigates the expression, regulation, function, and clinical implication of circPTK2 (hsa_circ_0005273) in CRC.

Compared with other RNAs, such as miRNAs and IncRNAs, circRNAs are more suitable as potential cancer biomarkers. First, the lack of 5′ or 3′ ends makes circRNAs highly resistant to RNase activity [6, 12, 28]. Second, they often express in a tissue- and developmental-stage-specific manner; and third, they are plentiful in various tissues and body fluids including blood, plasma, serum, and even in exosomes, making them potential candidates for liquid biopsy biomarkers [29, 30]. As expected, there are already many circRNAs recognized as cancer biomarkers. CiRS-7 and cIRchIPK3 were respectively identified to be promising prognostic biomarkers in CRC [17, 19]. In the present study, we found that circPTK2 might act as a potential biomarker for early diagnosis of CRC metastasis. A previous study reported that circPTK2 (hsa_circ_0003221) promotes the proliferation and migration of bladder cancer cells [31]. One recent study suggested circPTK2 (hsa_circ_0008305) inhibits TGF-β-induced epithelial–mesenchymal transition and metastasis by controlling TIF1γ in non-small cell lung cancer [32]. Together with our study, all these three circRNAs (hsa_circ_0005273, hsa_circ_0008305, and hsa_circ_0003221) were derived from the same pre-mRNA PTK2. However, they have distinctive sequences. CircRNA hsa_circ_0008305 with a spliced sequence length of 584 nt in circBase is back-spliced of seven exons (exons 8, 9, 10, 11, 12, 13 and 14) of PTK2. CircRNA hsa_circ_0005273 with a spliced sequence length of 357 nt is back-spliced of three exons (exons 27, 28, and 29). CircRNA hsa_circ_0003221 with a spliced sequence length of 625 nt is back-spliced of five exons (exons 3, 4, 5, 6 and 7). Therefore, the functions of these three circRNA may be distinguished.

CircRNAs have been reported to interact with different proteins to form specific circRNPs that subsequently influence modes of action of associated proteins [33]. For example, circANRIL was bound to the essential 60S preribosomal assembly factor pescadillo homolog 1 (PES1) and suppressed ribosome biogenesis in vascular smooth muscle cells and macrophages, resulting in nucleolar stress and cell death, which are key cellular events in atherosclerosis [14]. CircMbl was also found to be associated with multifunctional protein MBL, which promotes the biogenesis of circMbl that is produced from the same gene locus. This circRNA could then sponge out the excess MBL protein by binding to it [34]. Our results suggesting physical binding to circPTK2 to vimentin, which is distinguished from circPTK2 (hsa_circ_0008305), acting as a sponge for miR-429 / miR-200b-3p in non-small cell lung cancer cells and hereby inhibiting EMT in lung cancer cells [32]. Recently, some circRNAs with tumor suppressive properties have been found to play important roles in tumorigenesis and metastasis, and can be used as therapeutic targets for cancer. CircITGA7 was found to inhibit the proliferation and metastasis of CRC cells by inhibiting the Ras signaling pathway and promoting ITGA7 transcription. Furthermore, hsa_circ_0014717 suppressed CRC growth by upregulating P16 expression [35]. These indicate that circRNAs are gradually becoming carcinogenic stimulators or tumor suppressors in cancer.
Vimentin is a type 3 intermediate filament protein that is an critical marker of mesenchymal cells in EMT. It is responsible for maintaining cell shape and stabilizing cytoskeletal interactions. Vimentin serves as an organizer of many key proteins involved in cell attachment and migration [36]. Vimentin is a potential cancer therapeutic target, since it is overexpressed in a number of cancers, and influences cell shape and motility in the process of EMT that occurs during metastasis [37, 38]. Current studies have shown that phosphorylation of vimentin serine residues inhibits subunit polymerization, then promoting the decomposition of vimentin filaments and increasing the solubility of the protein [39]. For example, Protein kinase A (PKA) phosphorlylates vimentin mainly at Ser38 and Ser72 sites, resulting in decreased filament formation in vivo, which indicates that phosphorylation mainly regulates the decomposition of vimentin intermediate filaments [40]. During mitosis, CDK1 phosphorylated vimentin at Ser55. This phosphorylation provides a PLK binding site for vimentin-PLK interaction. PLK further phosphorylated vimentin at Ser82, which may be a memory phosphorylation site and lead to the marked disassembly of vimentin filaments [41, 42]. We found that circPTK2 (hsa_circ_0005273) promoted expression of vimentin via physically binding to its phosphorylation sites Ser38, Ser55 and Ser82.

Limitation of our study should be mentioned. It remains unclear that the regulatory mechanism of circPTK2 to promote CRC growth, and whether any miRNAs or other transcription factors are involved in the regulation of circPTK2 to metastatic process of CRC. CircPTK2 plays a part in tumor progression and metastasis. Therefore, how circPTK2 regulates CRC progression and metastasis warrants further investigation.

Conclusions
In summary, we reported that increased expression levels of hsa_circ_0005273, spliced from the pre-mRNA PTK2, was involved in the metastasis of colorectal cancer via physical binding to phosphorylation sites Ser38, Ser55 and Ser82 of vimentin. Our study provides an exploitable therapeutic target for CRC patients, despite that the underlying mechanisms need further investigation.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12943-020-1139-3.

Additional file 1: Figure S1. The circPTK2 is elevated in serum of CRC patients. (A) Levels of circPTK2 in serum from healthy controls (NOR) and CRC patients (CRC) in the testing, validation, and the combination set were detected by qPCR. (B) The abundance of circPTK2 in CRC patients with different clinical characteristics were further analyzed. Data are presented as ∆ΔCt by one-way ANOVA with three technical replicates.

Additional file 2: Figure S2. CircPTK2 promoted aggressive phenotypes of CRC cells in vitro. Cells were transfected with circPTK2 siRNA or circPTK2-overexpressing plasmid for 48 h. Then cells were harvested for annexin-V and PI staining. Cell apoptosis was detected with flow cytometry analysis. The cells were stained by crystal violet to evaluate cell proliferation, migration, and invasion capability. (A, B) The effect of circPTK2 knockdown on SW480 apoptosis. (C, D) The effect of circPTK2 overexpression on SW620 apoptosis. (E-H) Representative images and quantification results of the colony formation of cells. (I-L) Representative images and quantification results of the migration and invasion of cells. The data are the mean ± SEM. *P<0.05, **P<0.01, ***P<0.001. P values were calculated by one-way ANOVA.

Additional file 3: Figure S3. CircPTK2 promoted tumor growth in a xenograft mouse model. LOVO cells stably expressing luciferase were transfected with the indicated siRNAs and HCT15 cells stably expressing luciferase were transfected with the indicated overexpressing-plasmid. After 72 h, cells were injected into the tail veins of nude mice (n = 6). (A) Representative bioluminescence images of mice bearing LOVO cells were obtained. (B) Luciferase activity of tumor, liver, and lung was quantified in mice bearing LOVO cells. (C) Representative bioluminescence images of mice bearing HCT15 cells were obtained. (D) Luciferase activity of tumor, liver, and lung was quantified in mice bearing HCT15 cells. The data are the mean ± SEM. *P<0.05, **P<0.01, ***P<0.001. P values were calculated by one-way ANOVA.

Additional file 4: Figure S4. The mass spectrometry of vimentin. Each mass spectrum presents a peptide. The protein binding to circPTK2 was vimentin.

Additional file 5: Figure S5. CircPTK2 targeted vimentin protein to regulate growth and metastasis of CRC. (A-B) HCT15 cells were transfected with circPTK2 siRNA for 48 h. Cells were used for staining with crystal violet or injected into subcutaneous tissue of nude mice. Colony formation and tumor growth were detected. Colony formation and tumor growth of HCT15 cells were shown. (C-D) LOVO cells were transfected with circPTK2 siRNA plasmid as well as vimentin-overexpressing plasmid for 48 h. Cells were used for staining with crystal violet or injected into subcutaneous tissue of nude mice. Colony formation and tumor growth of LOVO cells were shown. P values were calculated by t test.

Additional file 6: Figure S6. CircPTK2 promoted MMP2/9 and CXCR4 expression in CRC cells. SW480 and HCT15 cells were transfected with circPTK2-overexpressing plasmid for 48 h, western blot assay showing circPTK2 overexpression up-regulated MMP2/9 and CXCR4.

Additional file 7: Table S1. Demographic information of colorectal cancer (CRC) and healthy control for PCR analysis.

Additional file 8: Table S2. Demographic information of colorectal cancer (CRC) patients subjected to TMA.

Additional file 9: Table S3. The detailed information of patients subjected to circRNA microarray analysis.

Additional file 10. Supplementary methods.

Abbreviations
circRNAs: circular RNAs; CRC: Colorectal cancer; EMT: Epithelial–mesenchymal transition; PDTX: Patient-derived tumor xenograft; TMA: Tissue microarray

Acknowledgements
Not applicable.

Data deposition
The circRNA microarray datasets reported in this paper have been deposited in the Gene Expression Omnibus (GEO) repository (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138589).
The authors declare no competing interests.

Funding
This work was financially supported by National Natural Science Foundation of China (Nos. 81472938, 815209304, 81673468, 81473230), National Science and Technology Major Projects for "Major New Drugs Innovation and Development" 2018ZX09201017–006, Fund of International Cooperation and Exchange of the National Natural Science Foundation of China (81861138017), co-funded by a grant from the Italian Ministry of Foreign Affairs and International Cooperation (PGR00962), China Pharmaceutical University-Southwest University Cooperative Research Project (No. 2242019K3DNZ1) and "Double First-Class" university project (No. CPU2018gf10 and CPU2018gy946).

Availability of data and materials
The data used or analyzed during this study are included in this article and available from the corresponding author upon reasonable request.

Ethics approval and consent to participate
Study protocols were approved by the Ethics Committee of Jiangsu Tumor Hospital and the Affiliated Hospital of the Xuzhou Medical College. Informed consent was obtained from all patients included in this study.

Consent for publication
All authors agree with the content of the manuscript.

Competing interests
The authors declare no competing interests.

Author details
1State Key Laboratory of Natural Medicines, Institute of Pharmaceutical Science, China Pharmaceutical University, Nanjing 211198, China. 2Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing 210009, China. 3School of Public Health, Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing 100069, People’s Republic of China. 4Beijing Key Laboratory of Environmental Toxicology, Capital Medical University, Beijing 100069, People’s Republic of China. 5School of Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou 221004, Jiangsu, China.

Received: 2 September 2019 Accepted: 16 January 2020
Published online: 23 January 2020

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018(68):394–424.
2. Goldstein DA, Zeichner SB, Bartnik CM, Neustadter E, Flowers CR. Metastatic colorectal cancer: a systematic review of the current therapies. Clin Colorectal Cancer. 2016;15:1–6.
3. Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17:79–92.
4. Chen LL. The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016;17:205–11.
5. Vicens Q, Westhof E. Biogenesis of circular RNAs. Cell. 2014;159:3–4.
6. Mermczak S, Jena M, Elefnioti A, Torri F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregerse L, Munschauer M, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333–8.
7. Zheng LL, Li JH, Wu J, Sun WJ, Liu S, Wang ZL, Zhou H, Yang JH, Qu LH. deepBase v2.0: identification, expression, evolution and function of small RNAs, lncRNAs and circular RNAs from deep-sequencing data. Nucleic Acids Res. 2016;44:D196–202.
8. Liu YC, Li JR, Sun CH, Andrews E, Chao RF, Lin FM, Weng SL, Hsu SD, Huang CC, Cheng C, et al. CircNet: a database of circular RNAs derived from transcriptome sequencing data. Nucleic Acids Res. 2016;44:D209–15.
9. Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, Zhong G, Yu B, Hu W, Dai L, et al. Comigration: exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2017;24:194.
10. Zhang Y, Zhang XQ, Chen T, Xiang JG, Yin XQ, Xing YH, Zhu S, Yang L, Chen LL. Circular intronic long noncoding RNAs. Mol Cell. 2013;51:792–805.
11. Hansen TB, Jensen TL, Clausen BH, Rasmussen BJ, Finsen B, Damaa GA, Kjems J. Natural RNA circles function as efficient microRNA sponges. Nature. 2014;149:384–8.
12. Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, Zhong G, Yu B, Hu W, Dai L, et al. Exon-intronic circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015;22:256–64.
13. Du WW, Yang W, Liu E, Yang Z, Dhalawi P, Yang BB. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. Nucleic Acids Res. 2016;44:2846–58.
14. Holdt LM, Stahringer A, Sass K, Pichler G, Kulak NA, Wilfert W, Kohlaiaer M, Herbst A, Nothoff BH, Nicolau A, et al. Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. Nat Commun. 2016;7:12429.
15. Hsiao KY, Lin YC, Gupta SK, Chang N, Yen L, Sun HS, Tsai SJ. Noncoding effects of circular RNA CDC66 promote Colon Cancer growth and metastasis. Cancer Res. 2017;77:2339–50.
16. Xie H, Ren X, Xin S, Lan X, Lu G, Lin Y, Liu S, Zeng Z, Liao W, Ding YQ, Liang L. Emerging roles of circRNA_001569 targeting mir-145 in the proliferation and invasion of colorectal cancer. Oncotarget. 2016;7:26680–91.
17. Weng W, Wei Q, Toden S, Yoshida K, Nagaoka T, Fujitara T, Tai S, Qin H, Ma Y, Goel A. Circular RNA cirs-7-a promising prognostic biomarker and a potential therapeutic target in colorectal Cancer. Clin Cancer Res. 2017;23:3918–28.
18. Zhang P, Zuo Z, Shang W, Wu A, Bi R, Wu J, Li S, Sun X, Jiang L. Identification of differentially expressed circular RNAs in human colorectal cancer. Tumour Biol. 2017;39:101048317694546.
19. Zeng K, Chen X, Xu M, Liu X, Hu X, Xu T, Sun H, Pan Y, He B, Wang S. CircHIPK3 promotes colorectal cancer growth and metastasis by sponging mir-7. Cell Death Dis. 2018;9:417.
20. Sun T, Sun BC, Zhao XL, Zhao N, Dong YX, Che N, Yao Z, Ma YM, Gu Q, Zong WK, Liu ZY. Promotion of tumor cell metastasis and vasuogenic mimicry by way of transcription coactivation by Bcl2 and V61: a study of hepatocellular carcinoma. Hepatolology. 2011;54:1690–706.
21. De Caene B, Bex G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13:97–110.
22. Lamouille S, Xu J, Dennis N. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–95.
23. Wu S, Meng Q, Zhang C, Sun H, Li R, Gao N, Yang H, Li X, Aschner M, Chen R, DR4 mediates the progression, invasion, metastasis and survival of colorectal cancer through the Sp1/NF1 switch axis on genomic loci. Int J Cancer. 2018;143:289–97.
24. Gabarra-Niecko V, Schaller MD, Duny JM. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev. 2003;22:559–74.
25. Mclean GW, Carraher NO, Avizeneite E, Evans J, Brunton VG, Frame MC. The role of focal-membrane kinase in cancer – a new therapeutic opportunity. Nat Rev Cancer. 2005;5:505–15.
26. Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 2014;14:598–610.
27. van Nirmwegem MJ, van de Water B. Focal adhesion kinase: a potential target in cancer therapy. Biochem Pharmacol. 2007;73:597–609.
28. Salaman J, Chen RE, Olsen MN, Wang PL, Brown PO. Cell-type specific features of circular RNA expression. PLoS Genet. 2013;9:e1003777.
29. Mermczak S, Papavasileiou P, Peters O, Rajewsky N. Identification and characterization of circular RNAs as a new class of putative biomarkers in human blood. PLoS One. 2015;10:e0141214.
30. Bahn JH, Zhang Q, Li F, Chan TM, Lin X, Kim Y, Wong DT, Xiao X. The landscape of microRNA, Piwi-interacting RNA, and circular RNA in human saliva. Chem. 2015;61:12429–30.
31. Xu ZQ, Yang MG, Liu HJ, Su CO. Circular RNA hsa_circ_0003221 (circPTK2) promotes the proliferation and migration of bladder cancer cells. J Cell Biochem. 2018;119:3317–25.
32. Wang L, Tong X, Zhou Z, Wang S, Lei Z, Zhang T, Liu Z, Zeng Y, Li C, Zhao J, et al. Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF-beta-induced...
epithelial-mesenchymal transition and metastasis by controlling TIF1gamma in non-small cell lung cancer. Mol Cancer. 2018;17:140.
33. Li X, Yang L, Chen LL. The biogenesis, functions, and challenges of circular RNAs. Mol Cell. 2018;71:428–42.
34. Ashwal-Fluss R, Meyer M, Pamuduri NR, Ivanov A, Bartok O, Hanan M, Eviant N, Menczak S, Rajewsky N, Kadener S. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;54:55–66.
35. Li Z, Ruan Y, Zhang H, Shen Y, Li T, Xiao B. Tumor-suppressive circular RNAs: mechanisms underlying their suppression of tumor occurrence and use as therapeutic targets. Cancer Sci. 2019;110:3630–8.
36. Kidd ME, Shumaker DK, Ridge KM. The role of vimentin intermediate filaments in the progression of lung cancer. Am J Respir Cell Mol Biol. 2014;50:1–6.
37. Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P, Foidart JM. Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res. 2003;63:2658–64.
38. Mendez MG, Kojima S, Goldman RD. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. 2010;24:1838–51.
39. Danielsson F, Peterson MK, Caldeira Araujo H, Lautenschlager F, Gad AKB. Vimentin diversity in health and disease. Cells. 2018;7,147.
40. Eriksson JE, He T, Trejo-Skalli AV, Harmala-Brasken AS, Hellman J, Chou YH, Goldman RD. Specific in vivo phosphorylation sites determine the assembly dynamics of vimentin intermediate filaments. J Cell Sci. 2004;117:919–32.
41. Yamaguchi T, Goto H, Yokoyama T, Sillje H, Hanisch A, Lidschmid A, Takai Y, Oguri T, Ngg EA, Inagaki M. Phosphorylation by Cdk1 induces Plk1-mediated vimentin phosphorylation during mitosis. J Cell Biol. 2005;171:431–6.
42. Oguri T, Inoko A, Shima H, Izawa J, Arimura N, Yamaguchi T, Inagaki N, Kaibuchi K, Kikuchi K, Inagaki M. Vimentin-Ser82 as a memory phosphorylation site in astrocytes. Genes Cells. 2006;11:531–40.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.